Clinical Trials for Ovarian Cancer

A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with advanced/metastatic solid tumors (endometrial, gastric, mCRPC, ovarian, colorectal, urothelial, biliary) receive datopotamab deruxtecan (anti‑TROP2 antibody–drug conjugate delivering a topoisomerase I inhibitor) as monotherapy or combined with agents such as capecitabine/5‑FU, bevacizumab ± platinum, prednisone (mCRPC), platinum in urothelial cancer, or bispecific PD‑1/CTLA‑4 (volrustomig) or PD‑1/TIGIT (rilvegostomig) immunotherapies. Key exclusions include active/untreated CNS disease, prior TROP2- or deruxtecan-based ADCs, significant ILD/pneumonitis history, and uncontrolled infections/comorbidities.

ClinicalTrials.gov ID: NCT05489211

RESOLVE: letRozole abEmaciclib combinationS in endOmetriaL and oVarian cancEr: A Multi-Cohort Phase 2 Study of Letrozole/Abemaciclib Alone and in Combination With Metformin, Zotatifin and Gedatolisib

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with recurrent/metastatic or treatment‑resistant endometrial cancer (primarily ER+) or low‑grade serous ovarian/fallopian tube/peritoneal carcinoma (ER+ preferred; ER‑ allowed in LGSOC) receive abemaciclib with letrozole, alone or combined with agents targeting PI3K/mTOR/DNA‑PK (samotolisib/LY3023414), pan‑class I PI3K/mTORC1/2 (gedatolisib), translational control via eIF4A (zotatifin), or metabolic/AMPK pathways (metformin). Most cohorts require ECOG 0–1, measurable disease, adequate organ function, and endocrine sensitivity markers; one cohort allows prior CDK4/6 inhibitor exposure.

ClinicalTrials.gov ID: NCT03675893

A Randomized Phase 2 Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Enrolling adult women with platinum‑resistant or refractory high‑grade serous ovarian, fallopian tube, or primary peritoneal cancer (measurable disease, ECOG 0–1) after at least one prior platinum regimen, randomized to CBX‑12 IV every 21 days at 100 vs 125 mg/m². CBX‑12 (alphalex exatecan) is a peptide–drug conjugate that targets acidic tumor microenvironments via pH‑low insertion peptide to deliver a topoisomerase I inhibitor payload.

ClinicalTrials.gov ID: NCT06315491

Multi-arm Phase 2 Study of Ubamatamab (REGN4018; MUC16×CD3 Bispecific Antibody) With or Without Additional Agents in Platinum-Resistant Ovarian Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with platinum‑resistant high‑grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer (ECOG 0–1) are randomized to ubamatamab (MUC16×CD3 T‑cell–redirecting bispecific) with prophylactic sarilumab, given alone or combined with bevacizumab, cemiplimab plus fianlimab (PD‑1/LAG‑3 blockade), or pegylated liposomal doxorubicin. Excludes clear cell/mucinous/carcinosarcoma histologies and active CNS disease; primary endpoint is RECIST ORR.

ClinicalTrials.gov ID: NCT06787612

A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (DENALI / ZN-c3-005 / GOG-3066)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with platinum‑resistant high‑grade serous ovarian, fallopian tube, or primary peritoneal cancer (ECOG 0–1) receive oral azenosertib (ZN‑c3), a selective WEE1 kinase inhibitor, as monotherapy on an intermittent schedule; Part 2 enrolls centrally confirmed Cyclin E1–positive tumors with dose selection (300 vs 400 mg) then expansion at the chosen dose. Prior bevacizumab and PARP inhibitor (if eligible) are required, with exclusions for primary platinum‑refractory disease and prior WEE1/ATR/PKMYT1/CHK1/2 inhibitors.

ClinicalTrials.gov ID: NCT05128825

Randomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (serous/endometrioid/clear cell), platinum-sensitive or -resistant, ≤3 prior lines, measurable disease, and ECOG 0–1 are randomized to pembrolizumab plus bevacizumab with or without CDX-1140. CDX-1140 is an investigational agonist anti-CD40 antibody intended to activate dendritic/B cells and augment T-cell antitumor responses.

ClinicalTrials.gov ID: NCT05231122

Phase 2, Randomized, Prospective, Open-Label, Parallel-Arm, Dose Optimization Study to Investigate the Safety, Tolerability, PK/PD, and Anti- Tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer.

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with recurrent, advanced platinum-resistant or platinum-ineligible high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer (ECOG 0–1) receive oral 2X-121 (stenoparib), a dual PARP1/2 and tankyrase 1/2 inhibitor, as monotherapy at either 600 mg/day or 800 mg/day. The study compares dosing to optimize safety, PK/PD, and antitumor activity; prior ADCs allowed and no more than one prior line in the platinum-resistant/ineligible setting.

ClinicalTrials.gov ID: NCT03878849

A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Physician's Choice of Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Women with platinum-resistant or refractory high‑grade epithelial ovarian, fallopian tube, or primary peritoneal cancer (ECOG 0–1, prior bevacizumab, ≥3 prior lines, measurable peritoneal disease) are randomized to intraperitoneal olvimulogene nanivacirepvec (oncolytic vaccinia immunotherapy) followed by platinum-doublet chemotherapy plus bevacizumab versus physician’s choice chemotherapy plus bevacizumab. Investigational Olvi‑Vec is designed to selectively replicate in tumor cells to induce oncolysis and stimulate antitumor immunity.

ClinicalTrials.gov ID: NCT05281471

An Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer (ECOG 0–1, measurable disease) are enrolled into biomarker-guided arms; the active arm tests ENB-003 (endothelin B receptor antagonist to enhance T-cell infiltration) plus toripalimab (PD-1 inhibitor), with prior PD-1/L1 exposure allowed if not stopped for severe immune toxicity and mandatory biopsies required. Closed arms included durvalumab with BA3011 (AXL-targeted CAB-MMAE ADC) or BA3021 (ROR2-targeted CAB-MMAE ADC).

ClinicalTrials.gov ID: NCT04918186

An Adaptive Clinical Platform Trial to Evaluate the Safety and Efficacy of COM701 as Monotherapy or Combination Therapy as Maintenance Therapy in Participants With Relapsed Platinum Sensitive Ovarian Cancer (PSOC)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with relapsed, platinum‑sensitive epithelial ovarian/fallopian tube/primary peritoneal cancer who achieved CR/PR after ≥4 cycles of their most recent platinum (after ≥2 prior platinum lines) and are bevacizumab/PARP‑experienced if eligible are randomized to maintenance COM701 vs placebo. COM701 is a humanized IgG4 monoclonal antibody targeting PVRIG (CD112R) on T/NK cells to restore DNAM‑1 axis antitumor immunity; dosing is IV q3w for up to 2 years, with future platform arms exploring combinations.

ClinicalTrials.gov ID: NCT06888921